Farmas USA

Dejo órden de compra a 7.01, para las que vendí ayer. Me piro un par de días a tierras malagueñas, a hacer el Caminito del Rey; cuidadme las NVAX.

Que pasada, hace poco estuvieron mis tios y es espectacular. Yo llevo semanas intentando reservar...

Disculpame pero deseo que no entre tu orden, no me guardes rencor ;-)

Al final dependeremos de los índices para que la subida (si la hay) se mantenga así que de momento me quedo quieto hasta ver como respira el mercado y como se mueve nuestra niña
NVAX

ya viste donde hizo max ayer el IBB, justo en la.bajista.
a ver si cerramos por encima de una p. vez!!

hey creo que Cramer dijo BUY BIOTECH

como ves HZNP para entrar ya?

Threshold Pharmaceuticals Enters Into Definitive Co-Promotion Agreement for Evofosfamide With Merck KGaA, Darmstadt, Germany

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/18/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that it finalized a definitive Co-Promotion Agreement for evofosfamide with Merck KGaA, Darmstadt, Germany pursuant to the companies' License and Co-Development Agreement entered into on February 2, 2012. Under the terms of the License and Co-Development Agreement, Threshold may co-promote evofosfamide (previously known as TH-302) in the U.S. subject to Food and Drug Administration (FDA) approval of evofosfamide. Evofosfamide is Threshold's investigational hypoxia-activated prodrug, which is currently the subject of two fully enrolled Phase 3 clinical trials in advanced soft tissue sarcoma and advanced pancreatic cancer for which Threshold expects to announce top-line data around the end of 2015.

Under the commercial leadership of Merck KGaA, Darmstadt, Germany, the terms of the License and Co-Development Agreement give Threshold the right, at its own cost, to field and be responsible for its own sales force in collaboration with Merck KGaA, Darmstadt, Germany's sales force in the U.S. pursuant to the terms of the new Co-promotion Agreement. Merck KGaA, Darmstadt, Germany remains responsible for all other commercial and medical affairs functions associated with the launch and promotion of evofosfamide. The development milestone payment and royalty payment portions of the License and Co-Commercialization Agreement remain the same. To date Threshold has received upfront and milestone payments of $110 million and can earn additional potential milestone payments of up to $440 million.

"We are pleased to have reached an agreement with our partner Merck KGaA, Darmstadt, Germany on definitive terms for our option to co-promote evofosfamide in the U.S.," said Barry Selick, Ph.D., Chief Executive Officer at Threshold. "The ability to co-promote and field a sales force represents one of two key options allowing Threshold to participate in the commercial phase of evofosfamide's lifecycle should it receive FDA approval. Importantly, the license agreement also provides us with an option to co-commercialize evofosfamide in the U.S., depending upon achieving certain milestones, which would allow us to share in up to fifty percent of the profits from the sale of the drug. Threshold is well positioned to integrate a commercial arm to its oncology discovery and development organization."

a falta de apenas mes y medio para liberar 2 fases 3 sabemos que ya han hecho solicitud de NDA y ahora cierran terminos ambas partes para ir a mercado

por favor, alguien ve alguna pega en todo esto?
yo no la veo!!!
:)

si esto no anima el precio ya no se lo que lo hara ...

THLD

THLD

Framus, esto es un blanco y en botella???? o todavía puede haber gato encerrado????